etbx-021
Vaccineexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02751528)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- etbx-021
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03563144 | Phase 2 | Aug 31, 2018 | NantWorks |
| NCT03586869 | Phase 1/Phase 2 (Phase 2) | Jul 28, 2018 | NantWorks |
| NCT03563157 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03387111 | Phase 1/Phase 2 (Phase 2) | Jan 13, 2018 | NantWorks |
| NCT03197584 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2017 | NantWorks |
| NCT03197571 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2017 | NantWorks |
| NCT02751528 | Phase 1 | Dec 1, 2016 | NantWorks |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NantWorks | For profit | 7 | 7 | 2 | 2016 |
1 organizations
Page 1 / 1